Nxera Pharma Statistics
Total Valuation
Nxera Pharma has a market cap or net worth of JPY 85.41 billion. The enterprise value is 117.20 billion.
Market Cap | 85.41B |
Enterprise Value | 117.20B |
Important Dates
The next estimated earnings date is Thursday, August 7, 2025.
Earnings Date | Aug 7, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Nxera Pharma has 89.90 million shares outstanding. The number of shares has increased by 6.46% in one year.
Current Share Class | 89.90M |
Shares Outstanding | 89.90M |
Shares Change (YoY) | +6.46% |
Shares Change (QoQ) | -0.00% |
Owned by Insiders (%) | 10.46% |
Owned by Institutions (%) | 29.80% |
Float | 73.00M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 40.50 |
PS Ratio | 2.77 |
PB Ratio | 1.27 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -50.58 |
EV / Sales | 3.80 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -21.35 |
Financial Position
The company has a current ratio of 3.72, with a Debt / Equity ratio of 0.99.
Current Ratio | 3.72 |
Quick Ratio | 2.83 |
Debt / Equity | 0.99 |
Debt / EBITDA | n/a |
Debt / FCF | -12.07 |
Interest Coverage | -5.36 |
Financial Efficiency
Return on equity (ROE) is -3.49% and return on invested capital (ROIC) is -2.09%.
Return on Equity (ROE) | -3.49% |
Return on Assets (ROA) | -1.90% |
Return on Invested Capital (ROIC) | -2.09% |
Return on Capital Employed (ROCE) | -3.46% |
Revenue Per Employee | 79.76M |
Profits Per Employee | -5.99M |
Employee Count | 374 |
Asset Turnover | 0.21 |
Inventory Turnover | 1.48 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.61% in the last 52 weeks. The beta is 0.27, so Nxera Pharma's price volatility has been lower than the market average.
Beta (5Y) | 0.27 |
52-Week Price Change | -33.61% |
50-Day Moving Average | 850.68 |
200-Day Moving Average | 1,072.50 |
Relative Strength Index (RSI) | 69.65 |
Average Volume (20 Days) | 868,740 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nxera Pharma had revenue of JPY 30.87 billion and -2.32 billion in losses. Loss per share was -25.79.
Revenue | 30.87B |
Gross Profit | 22.83B |
Operating Income | -4.54B |
Pretax Income | -4.02B |
Net Income | -2.32B |
EBITDA | -457.00M |
EBIT | -4.54B |
Loss Per Share | -25.79 |
Balance Sheet
The company has 34.47 billion in cash and 66.26 billion in debt, giving a net cash position of -31.80 billion or -353.71 per share.
Cash & Cash Equivalents | 34.47B |
Total Debt | 66.26B |
Net Cash | -31.80B |
Net Cash Per Share | -353.71 |
Equity (Book Value) | 67.07B |
Book Value Per Share | 746.05 |
Working Capital | 38.90B |
Cash Flow
In the last 12 months, operating cash flow was -4.90 billion and capital expenditures -589.00 million, giving a free cash flow of -5.49 billion.
Operating Cash Flow | -4.90B |
Capital Expenditures | -589.00M |
Free Cash Flow | -5.49B |
FCF Per Share | -61.06 |
Margins
Gross margin is 73.95%, with operating and profit margins of -14.71% and -7.51%.
Gross Margin | 73.95% |
Operating Margin | -14.71% |
Pretax Margin | -13.03% |
Profit Margin | -7.51% |
EBITDA Margin | -1.48% |
EBIT Margin | -14.71% |
FCF Margin | n/a |
Dividends & Yields
Nxera Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -6.46% |
Shareholder Yield | n/a |
Earnings Yield | -2.71% |
FCF Yield | -6.43% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on June 27, 2018. It was a forward split with a ratio of 4.
Last Split Date | Jun 27, 2018 |
Split Type | Forward |
Split Ratio | 4 |
Scores
Nxera Pharma has an Altman Z-Score of 1.1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.1 |
Piotroski F-Score | n/a |